CMV Prophylaxis in Kidney Transplant: Examining New Solutions to an Old Problem
Post-transplant cytomegalovirus (CMV) infection afflicts as high as 80% of kidney organ transplant recipients, resulting in life-threatening direct complications, long-term negative outcomes, and significant morbidity and mortality. Current first-line antivirals administered to patients in post-treatment prophylaxis are associated with toxicity …